Αρχειοθήκη ιστολογίου

Αναζήτηση αυτού του ιστολογίου

Σάββατο 8 Δεκεμβρίου 2018

A Specific Circulating MicroRNA Cluster Is Associated to Late Differential Cardiac Response to Doxorubicin-Induced Cardiotoxicity In Vivo

Background. Cardiotoxicity is a detrimental side effect of the anticancer drug doxorubicin (DOX), characterized by progressive heart dysfunction. Circulating microRNAs (miRNAs) are recognized as potential biomarkers of cardiac disease; thus, we aimed to investigate their association with late cardiotoxicity in an animal model of disease. Methods. Twenty C57BL/6 female mice were administered with 24 mg/kg cumulative dose of DOX or saline during 2 weeks, followed by a recovery period of one month (T42). Echocardiography was performed at baseline and at T42, and plasma samples were collected at T42. The selection of all miRNAs of interest was conducted by literature overview and by screening, followed by RT-qPCR validation. Results. The analysis of cardiac function at T42 evidenced five DOX-treated animals indistinguishable (NoTox) from controls (CTRLs), while four presented heart impairment (Tox). Our analyses identified eight dysfunction-associated plasma miRNAs. In particular, seven miRNAs were found downregulated in comparison to CTRLs, miR-1-3p, miR-122-5p, miR-127-3p, miR-133a-3p, miR-215-5p, miR-455-3-p, and miR-499a-5p. Conversely, miR-34a-5p showed increased levels in Tox plasma samples. Noteworthy, we determined a cluster composed of miR-1-3p, miR-34a-5p, miR-133a-3p, and miR-499a-5p that distinguished with high-accuracy Tox from NoTox mice. Conclusion. This is the first study indicating that, similarly to what is observed in patients, DOX-administered animals present a differential cardiac response to treatment. Moreover, our results indicate the presence of specific plasma miRNAs whose expression reflect the presence of cardiac dysfunction in response to drug-induced injury.

https://ift.tt/2B5EX7R

1 simple question to increase audience participation

Tackling the difficult challenge of encouraging participation by asking this simple question and waiting for a response

https://ift.tt/2L4yaQx

Predictors of early recurrence after strictureplasty for Crohn’s disease of the small bowel during the years of biologics

The identification of patients prone to early recurrence of Crohn's disease at the site of a strictureplasty is fundamental in the clinical practice.

https://ift.tt/2G4ysHW

Changes in event-related potentials during dual task walking in aging and Parkinson's disease

It has been theorized that walking in everyday life conditions requires higher cognitive processes that utilizes a complex neural network that incorporates cognitive and motor information (Woollacott and Shumway-Cook, 2002; Yogev-Seligmann et al., 2008). Most evidence supporting this notion relies on behavioral studies stemming from dual-task paradigms during walking to increase cognitive demands. These studies show that adding a simultaneous task to walking taxes executive function and attention and leads to changes in gait performance (Hausdorff et al., 2008; Yogev-Seligmann et al., 2008).

https://ift.tt/2zMPGnW

Increased Emg Intermuscular Coherence and Reduced Signal Complexity in Parkinson’s Disease

The severity of the symptoms of Parkinson's disease (PD) are currently clinically evaluated using subjective scores such as the Movement Disorders Society Unified-Parkinson's-Disease-Rating-Scale (MDS-UPDRS) (Goetz et al., 2008). The semi-quantitative score, MDS-UPDRS III, provides a macro view of motor control without characterising specific patient kinematics. There is a recognised need for more quantitative measures to evaluate motor symptoms in PD which can provide insights into changes in neural control and provide an objective biomarker for diagnosis.

https://ift.tt/2Pr7Hgk

Significant antitumor effect of an antibody against TMEM180, a new colorectal cancer‐specific molecule

Summary

The present state of therapy for colorectal cancer (CRC) is far from satisfactory, highlighting the need for new targets for this disease. We identified a new colorectal cancer (CRC)‐specific molecule, TMEM180, a predicted eleven‐pass transmembrane protein that apparently functions as a cation symporter. We developed the anti‐TMEM180 monoclonal antibody (mAb) and then succeeded in humanizing the mAb. Immunohistochemistry (IHC) in CRC with the mAb showed a similar positivity rate as compared with anti‐EGFR mAb and the IHC with anti‐TMEM180 mAb did not show staining in major organs used in this study. The immune‐electron microscopy clearly indicated that TMEM180 was present on the tumor exosome. The TMEM180 promoter region contains ten hypoxia‐responsive element consensus sequences; accordingly SW480 cells upregulated TMEM180 under low‐oxygen conditions. The anti‐TMEM180 mAb possessed in vitro ADCC and CDC activity, and SW480 CRC xenografts were eradicated by the mAb.

These data indicate that TMEM180 may be a new CRC marker and that a mAb against this protein could be used as antibody‐based therapeutic against CRC.

This article is protected by copyright. All rights reserved.



https://ift.tt/2BXUIiG

In This Issue



https://ift.tt/2RLgjAy